Sarepta announces sale of priority review voucher for $102M

Sarepta Therapeutics announced it had completed the sale of its Rare Pediatric Disease Priority Review Voucher PRV Sarepta received a payment of $102M upon completion of the sale. Sarepta was awarded the PRV following U.S. Food and Drug Administration FDA accelerated approval of ELEVIDYS or delandistrogene moxeparvovec-rokl, for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophyor DMD, with a confirmed mutation in the DMD gene. Under the Rare Pediatric Disease Priority Review Voucher Program, FDA awards priority review vouchers to sponsors of rare pediatric disease product applications that meet certain criteria. The program is intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. PRVs can be redeemed to receive priority review of a subsequent marketing application for a different product, sold or transferred. Sarepta will invest proceeds from the sale of the PRV into our R&D efforts to support the development of more transformative therapies.